Plus Therapeutics (PSTV)
3.87
0.00 (0.00%)
Upcoming Events
Latest Headlines
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
September 10, 2026 7:15 AM - Globe NewsWire
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
August 20, 2026 7:30 AM - Globe NewsWire
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
August 14, 2026 4:15 PM - Globe NewsWire
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
August 13, 2026 7:30 AM - Globe NewsWire
Cerenome picks XiFin for billing services on CNSide platform
August 6, 2026 7:31 AM - StreetInsider
Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
August 6, 2026 7:30 AM - Globe NewsWire
Plus Therapeutics rebrands to Cerenome, changes ticker to CNSY
July 31, 2026 8:31 AM - StreetInsider
Cerenome Launches as an Integrated CNS Oncology Company
July 31, 2026 8:30 AM - Globe NewsWire
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
July 28, 2026 7:30 AM - Globe NewsWire
Plus Therapeutics CNSide assay gains Medical Mutual coverage in Ohio
July 21, 2026 7:30 AM - StreetInsider
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
July 21, 2026 7:30 AM - Globe NewsWire
Plus Therapeutics and Genomic Testing Cooperative to expand CSF platform
July 16, 2026 7:31 AM - StreetInsider
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
July 16, 2026 7:30 AM - Globe NewsWire
Plus Therapeutics highlights CNSide role after NCCN guideline update
July 14, 2026 7:32 AM - StreetInsider
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
July 14, 2026 7:30 AM - Globe NewsWire
Form 4 PLUS THERAPEUTICS, INC. For: Jul 01 Filed by: Guse Kyle
July 1, 2026 4:31 PM - SEC Filing
Form 4 PLUS THERAPEUTICS, INC. For: Jul 01 Filed by: ANDREWS RONALD ASBURY
July 1, 2026 4:31 PM - SEC Filing
Form 4 PLUS THERAPEUTICS, INC. For: Jul 01 Filed by: van Es-Johansson An
July 1, 2026 4:31 PM - SEC Filing
Form 4 PLUS THERAPEUTICS, INC. For: Jul 01 Filed by: HEDRICK MARC H
July 1, 2026 4:31 PM - SEC Filing
Form 4 PLUS THERAPEUTICS, INC. For: Jul 01 Filed by: Clowes Howard
July 1, 2026 4:31 PM - SEC Filing
Form 4 PLUS THERAPEUTICS, INC. For: Jul 01 Filed by: Hawkins Richard J
July 1, 2026 4:30 PM - SEC Filing
Form 4 PLUS THERAPEUTICS, INC. For: Jul 01 Filed by: Sims Andrew John Hugh MacIntyre
July 1, 2026 4:30 PM - SEC Filing
Plus Therapeutics to rebrand as Cerenome, trade as CNSY on Aug. 3
June 30, 2026 7:31 AM - StreetInsider
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
June 30, 2026 7:30 AM - Globe NewsWire
Plus Therapeutics unit signs national coverage deal with Elevance Health
June 25, 2026 7:31 AM - StreetInsider
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
June 25, 2026 7:30 AM - Globe NewsWire
Plus Therapeutics to Provide Business Update Call on June 30, 2026
June 23, 2026 7:30 AM - Globe NewsWire
Form S-8 PLUS THERAPEUTICS, INC.
June 18, 2026 4:31 PM - SEC Filing
Full Article List
